Type 2 Diabetes
Explore facts and recommendations for pharmacological treatments for type 2 diabetes.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Get Smart: Leveraging New Technologies to Optimize Diabetes Management (IME Content)
Review of continuous glucose monitoring, various insulin delivery methods and associated ADA, EASD and AACE guidance. Also highlights patient and provider barriers to the use of diabetes technology.
Contemporary Diabetes Management With Smart Technology: Case Studies in Continuous Glucose Monitoring (IME Content)
Various case studies to explore the use of Continuous Glucose Monitoring.
Smart Technology for Diabetes Management: Advances for Insulin Delivery Methods (IME Content)
Comprehensive overview of various insulin delivery devices.
Degludec Cardiovascular Outcomes Trial (DEVOTE) Overview
Summary and highlights from a clinical trial comparing the cardiovascular safety of degludec and glargine.
SWITCH-1 and SWITCH-2 Trial Overview
Summary and highlights from a clinical trial comparing the effects of degludec and glargine on hypoglycemia.
Continuing Education
Find accredited opportunities in type 2 diabetes education.
Type 2 Diabetes
Safety of GLP-1 RAs in Cardiovascular Outcome Trials (CVOTs)
Review of trials evaluating the safety of GLP-1 RAs in patients with type 2 diabetes and established cardiovascular disease and/or cardiovascular risk factors.
Overview of Select Modern Non-Insulin Antidiabetic Drugs (NIADs)
Detailed breakdown of NIAD types, with quick-reference tables covering mechanism of action, efficacy, and more.
Heart Failure and GLP-1 RAs
Detailed review of heart failure, its relationship to type 2 diabetes (T2D), and the effect of GLP-1 RAs on heart failure in T2D patients.
Properties of Anti-Hyperglycemic Agents
Chart comparing efficacy and considerations for 7 types of agents.
Type 2 Diabetes
Ozempic® Mechanism of Action
This video discusses the mechanism of action and mechanism of protraction of Ozempic®
RYBELSUS® Mechanism of Action
This video discusses the mechanism of action of RYBELSUS®
RYBELSUS® Mechanism of Absorption
This video discusses the mechanism of absorption of RYBELSUS®.
Pharmakinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for RYBELSUS®
This video describes PK/PD considerations that can impact the dosing of RYBELSUS®.
Drug Interactions With RYBELSUS®
This video reviews potential drug-drug interactions with Rybelsus®
RYBELSUS® vs. Placebo in Drug-Naïve Adults (PIONEER 1 Study)
This video discusses the trial-design and outcomes of the PIONEER 1 study. PIONEER 1 was a 26-week, phase 3a, randomized, double-blind, parallel group, multinational trial in 703 adult patients with type 2 diabetes managed with diet and exercise alone.
RYBELSUS® 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)
This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.
RYBELSUS® vs. Sitagliptin 100 mg (PIONEER 3 Study)
This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.
RYBELSUS® 14 mg vs. Victoza® 1.8 mg vs. Placebo (PIONEER 4 Study)
This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.
RYBELSUS® 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)
This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.
Cardiovascular Safety of RYBELSUS® vs. Placebo (PIONEER 6 Study)
This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.
Flexible Dosing of RYBELSUS® vs. Sitagliptin 100 mg (PIONEER 7 Study)
This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.
RYBELSUS® vs. Placebo as Add-on to Insulin (PIONEER 8 Study)
This video discusses the trial-design and outcomes of the PIONEER 8 study. PIONEER 8 was a 52-week, phase 3a, randomized, double-blind, parallel-group, multinational trial enrolling 731 adults with type 2 diabetes.
Looking for additional resources?
Explore other libraries or search the Exchange.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit https://www.novonordisk-us.com/contact-us.html or call 1-800-727-6500
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
